VEGF-A splicing: the key to anti-angiogenic therapeutics? - Wikidata - wikimedia - TriplyDB

VEGF-A splicing: the key to anti-angiogenic therapeutics?

VEGF-A splicing: the key to anti-angiogenic therapeutics?

http://www.wikidata.org/entity/Q37035757

about

AVISPA: a web tool for the prediction and analysis of alternative splicing Functional Translational Readthrough: A Systems Biology Perspective Alternative RNA splicing: contribution to pain and potential therapeutic strategy Biomarkers of Angiogenesis in Colorectal Cancer The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis Splicing Regulators and Their Roles in Cancer Biology and Therapy Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Splice isoforms as therapeutic targets for colorectal cancer Therapeutic angiogenesis: controlled delivery of angiogenic factors.Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy Specific and Modular Binding Code for Cytosine Recognition in Pumilio/FBF (PUF) RNA-binding Domains Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged Transcriptional regulation of VEGFA by the endoplasmic reticulum stress transducer OASIS in ARPE-19 cells Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340)VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Overexpression of VEGF165b in podocytes reduces glomerular permeability.Neurovascular abnormalities in brain disorders: highlights with angiogenesis and magnetic resonance imaging studies.Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization.RNA-Sequencing data supports the existence of novel VEGFA splicing events but not of VEGFAxxxb isoforms.Anticipatory affect: neural correlates and consequences for choice Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.Let it flow: Morpholino knockdown in zebrafish embryos reveals a pro-angiogenic effect of the metalloprotease meprin alpha2.Recombinant human VEGF165b inhibits experimental choroidal neovascularization Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response.Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina.TNF-α-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulation Refining orthologue groups at the transcript level.Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.Expression profiling after activation of amino acid deprivation response in HepG2 human hepatoma cells Therapeutic potential of manipulating VEGF splice isoforms in oncology VEGF in the lung: a role for novel isoforms The role of mRNA splicing in prostate cancer.

P2860

Q21183995-330968FD-BEA0-4678-8793-1C86D0A60756 Q26739061-CE45B7CE-8074-4F5B-BC68-9BE8E87B559F Q26744085-0B624EF0-D002-4BC6-8153-0B13231229D2 Q26778891-C8B4B348-7613-4052-AD40-D6255B00EC9C Q26796921-0246E8BA-A2FD-46F3-AEBF-4077B478E600 Q26798158-5C97D559-3A14-4213-B877-75BE05C35255 Q26823757-C3A39465-A0BB-41E8-ABB2-6CBB4DAF53CC Q27000351-B7639E77-1AF1-4B82-89B5-B0B6783ABBB5 Q27006500-A7AE2DFA-48A7-47E5-B9A1-494E20C3D45E Q27023731-2377B2B0-DEBB-4F0D-A88D-71546925CC29 Q27342809-48C86436-F8CD-4E98-B24A-D51EBF3ED7AA Q27666276-57BC9E84-E124-4FE8-B617-609DDF6E9650 Q27666758-552D9983-EC56-4CCE-9A2A-E6F2806E86D9 Q28251240-D48FD2DA-BC8E-4BB1-A1C3-F13C28EF94F5 Q28297381-A4DCF51C-C378-485B-8B20-41B95C28061B Q28485361-5259AF05-D3BB-4796-9523-D15712AF4778 Q28513991-C7A59AE4-8E4B-49C3-955C-157E39F4D1AE Q28547020-6AA22995-1CE5-41DF-9194-A549E457CBF3 Q30275233-8393B310-7848-439F-94D7-89099EE4DD11 Q30437567-2A79FE79-3705-4BFC-850D-BE6BAD4A3242 Q30455612-46DFABEE-ECA1-4380-A542-9E0EBF6122B0 Q30497786-DEF2B786-1A1F-408C-B8F2-D74DDD105063 Q30653662-F20A277C-1F93-4CFF-A40F-A9C83E616869 Q30671049-54FDC49B-9D3C-4F31-A986-B712051627D5 Q30912245-99D0FE95-145E-47A7-BF78-0714216873E4 Q31036498-9E58B967-EA1A-400A-9EDB-E1229B94BF55 Q31168175-A631F1F7-06CA-4F2A-B41A-86E58C282705 Q33373233-248D0072-EBE1-4FFE-94C0-5E6C39249DCE Q33487136-217D742E-8AC6-4466-9B48-D30895E0476C Q33526257-BA646D73-692B-4B86-8B2B-D5E86C43DDCE Q33541827-C591FAD5-E299-4C7A-A094-91CC74A47A77 Q33686864-7FCD3366-5CB7-445B-B324-53D87049435E Q33742338-2295FC06-FE49-4143-9298-4A7664CC140A Q33753821-5989B498-2C0F-4727-BA6F-0ED584AC43B2 Q33766662-D4A62E16-C475-4953-BEE0-10A4A7977BC3 Q33828636-AFDCBF82-1D67-4428-913E-DDEDF8D32D71 Q33847650-F5636507-424F-4E43-95A5-9D67BBD03416 Q33888458-B1BB76A7-50AE-4E79-83A3-A363D205C4D0 Q33916926-3FA62FD8-6D03-4AA8-8B76-96D6899E2A43 Q33922376-6D7F4F69-EDA3-4B08-8335-FA0C7EDE56D1

P2860

VEGF-A splicing: the key to anti-angiogenic therapeutics?

http://www.wikidata.org/entity/Q37035757

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

VEGF-A splicing: the key to anti-angiogenic therapeutics?

@en

VEGF-A splicing: the key to anti-angiogenic therapeutics?

@nl

type

label

VEGF-A splicing: the key to anti-angiogenic therapeutics?

@en

VEGF-A splicing: the key to anti-angiogenic therapeutics?

@nl

prefLabel

VEGF-A splicing: the key to anti-angiogenic therapeutics?

@en

VEGF-A splicing: the key to anti-angiogenic therapeutics?

@nl

P1433

Q37035757-4334FABD-E9DA-4B70-BD13-7F4AE13CF9AA

P1476

Q37035757-3B19DB34-4CEA-4470-A333-22E4654087CA

P2093

Q37035757-5B56F728-3B45-44B8-975C-5006B0710388

Q37035757-D4E0B782-2C7E-47E0-8FD0-BE19E642513F

P2860

Q37035757-00F8F933-EEC9-4361-90FC-6970F7CF2CBF

Q37035757-0516ADE2-6A12-4EBB-B7AC-F72A10EE5E0E

Q37035757-0F7D56D1-8700-494C-813D-1A97273FD66F

Q37035757-1738FADB-05C9-4696-B82C-B77FC6FB816E

Q37035757-18A203AB-7FD9-40CF-8FC1-CC3F6AD55BED

Q37035757-19E61881-4ECC-4EF1-97B3-2BC22AE50759

Q37035757-1A0A0B53-BF13-445B-BB1F-2FBFDB65D580

Q37035757-1AF9910F-9AFB-456B-BA1C-81069BFEA693

Q37035757-1EECE35E-60CB-4FD9-94ED-43DEE90F95A3

Q37035757-234C33BC-05CE-43ED-BA4E-1B559C38071C

P2888

Q37035757-62484B3E-BF3A-406B-A47E-D4ABEF45C171

P304

Q37035757-8620E6F2-F146-4A9D-BFC6-617CE061758B

P31

Q37035757-E0D2E7DB-7B42-4AC4-9E14-D2C8A60B8699

P356

Q37035757-5E33040C-C600-4668-BCAF-C11D8F7E40D2

P407

Q37035757-2939E00E-A44B-4959-81E1-D0FC2B14BF88

P433

Q37035757-ADBC8D1D-BE15-49BA-B2A4-9C1A47A15306

P478

Q37035757-7383A70D-170E-4FF9-950C-096B00E359F7

P577

Q37035757-08843A64-4F86-407F-86C8-8CFA1457722B

P5875

Q37035757-5B667E63-3DD8-4BB2-B8DA-CA4D099CF46C

P698

Q37035757-8C8189ED-4945-4A45-BF38-A514E1C8F44B

P932

Q37035757-C7AC067C-E9C7-48C0-9AE9-FDFDCB68B187

P356

P1433

Nature Reviews Cancer

P1476

VEGF-A splicing: the key to anti-angiogenic therapeutics?

@en

P2093

David O Bates

http://www.w3.org/2001/XMLSchema#string

Steven J Harper

http://www.w3.org/2001/XMLSchema#string

P2860

Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth

VEGF inhibition and renal thrombotic microangiopathy

Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity

The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding

Solution structure of the heparin-binding domain of vascular endothelial growth factor

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

P2888

P304

880-887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRC2505

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23387459

http://www.w3.org/2001/XMLSchema#string

P698

18923433

http://www.w3.org/2001/XMLSchema#string

P932

2613352

http://www.w3.org/2001/XMLSchema#string